STUDY OBJECTIVES: We investigated if donepezil, a long-acting orally administered cholinesterase inhibitor, would reduce episodic memory deficits associated with 24 h of sleep deprivation. DESIGN: Double-blind, placebo-controlled, crossover study involving 7 laboratory visits over 2 months. Participants underwent 4 functional MRI scans; 2sessions (donepezil or placebo) followed a normal night's sleep, and 2 sessions followed a night of sleep deprivation. SETTING: The study took place in a research laboratory. PARTICIPANTS: 26 young, healthy volunteers with no history of any sleep, psychiatric, or neurologic disorders. INTERVENTIONS: 5 mg of donepezil was taken once daily for approximately 17 days. MEASUREMENTS AND RESULTS: Subjects were scanned while performing a semantic judgment task and tested for word recognition outside the scanner 45 minutes later. Sleep deprivation increased the frequency of non-responses at encoding and impaired delayed recognition. No benefit of donepezil was evident when participants were well rested. When sleep deprived, individuals who showed greater performance decline improved with donepezil, whereas more resistant individuals did not benefit. Accompanying these behavioral effects, there was corresponding modulation of task-related activation in functionally relevant brain regions. Brain regions identified in relation to donepezil-induced alteration in non-response rates could be distinguished from regions relating to improved recognition memory. This suggests that donepezil can improve delayed recognition in sleep-deprived persons by improving attention as well as enhancing memory encoding. CONCLUSIONS:Donepezil reduced decline in recognition performance in individuals vulnerable to the effects of sleep deprivation. Additionally, our findings demonstrate the utility of combined fMRI-behavior evaluation in psychopharmacological studies.
RCT Entities:
STUDY OBJECTIVES: We investigated if donepezil, a long-acting orally administered cholinesterase inhibitor, would reduce episodic memory deficits associated with 24 h of sleep deprivation. DESIGN: Double-blind, placebo-controlled, crossover study involving 7 laboratory visits over 2 months. Participants underwent 4 functional MRI scans; 2 sessions (donepezil or placebo) followed a normal night's sleep, and 2 sessions followed a night of sleep deprivation. SETTING: The study took place in a research laboratory. PARTICIPANTS: 26 young, healthy volunteers with no history of any sleep, psychiatric, or neurologic disorders. INTERVENTIONS: 5 mg of donepezil was taken once daily for approximately 17 days. MEASUREMENTS AND RESULTS: Subjects were scanned while performing a semantic judgment task and tested for word recognition outside the scanner 45 minutes later. Sleep deprivation increased the frequency of non-responses at encoding and impaired delayed recognition. No benefit of donepezil was evident when participants were well rested. When sleep deprived, individuals who showed greater performance decline improved with donepezil, whereas more resistant individuals did not benefit. Accompanying these behavioral effects, there was corresponding modulation of task-related activation in functionally relevant brain regions. Brain regions identified in relation to donepezil-induced alteration in non-response rates could be distinguished from regions relating to improved recognition memory. This suggests that donepezil can improve delayed recognition in sleep-deprived persons by improving attention as well as enhancing memory encoding. CONCLUSIONS:Donepezil reduced decline in recognition performance in individuals vulnerable to the effects of sleep deprivation. Additionally, our findings demonstrate the utility of combined fMRI-behavior evaluation in psychopharmacological studies.
Authors: Michael W L Chee; Jiat Chow Tan; Hui Zheng; Sarayu Parimal; Daniel H Weissman; Vitali Zagorodnov; David F Dinges Journal: J Neurosci Date: 2008-05-21 Impact factor: 6.167
Authors: A D Wagner; D L Schacter; M Rotte; W Koutstaal; A Maril; A M Dale; B R Rosen; R L Buckner Journal: Science Date: 1998-08-21 Impact factor: 47.728
Authors: Christina Schmidt; Fabienne Collette; Yves Leclercq; Virginie Sterpenich; Gilles Vandewalle; Pierre Berthomier; Christian Berthomier; Christophe Phillips; Gilberte Tinguely; Annabelle Darsaud; Steffen Gais; Manuel Schabus; Martin Desseilles; Thien Thanh Dang-Vu; Eric Salmon; Evelyne Balteau; Christian Degueldre; André Luxen; Pierre Maquet; Christian Cajochen; Philippe Peigneux Journal: Science Date: 2009-04-24 Impact factor: 47.728
Authors: Adrienne M Tucker; Brian C Rakitin; Robert C Basner; Yunglin Gazes; Jason Steffener; Yaakov Stern Journal: Behav Brain Res Date: 2010-11-11 Impact factor: 3.332
Authors: Michael W L Chee; Cindy S F Goh; Praneeth Namburi; Sarayu Parimal; Katharina N Seidl; Sabine Kastner Journal: Neuroimage Date: 2011-06-30 Impact factor: 6.556
Authors: Nisha K Ramakrishnan; Krisztina Marosi; Csaba J Nyakas; Chantal Kwizera; Philip H Elsinga; Kiichi Ishiwata; Paul G M Luiten; Rudi A J O Dierckx; Aren van Waarde Journal: Mol Imaging Biol Date: 2015-04 Impact factor: 3.488
Authors: Adam J Krause; Eti Ben Simon; Bryce A Mander; Stephanie M Greer; Jared M Saletin; Andrea N Goldstein-Piekarski; Matthew P Walker Journal: Nat Rev Neurosci Date: 2017-05-18 Impact factor: 34.870
Authors: A Reches; I Laufer; K Ziv; G Cukierman; K McEvoy; M Ettinger; R T Knight; A Gazzaley; A B Geva Journal: Neuroimage Date: 2013-11-21 Impact factor: 6.556
Authors: Amandine Valomon; Sebastian C Holst; Alessandro Borrello; Susanne Weigend; Thomas Müller; Wolfgang Berger; Michael Sommerauer; Christian R Baumann; Hans-Peter Landolt Journal: Neuropsychopharmacology Date: 2018-02-05 Impact factor: 7.853